212 related articles for article (PubMed ID: 16709035)
41. Initial management of childhood brain tumors: neurosurgical considerations.
Nejat F; El Khashab M; Rutka JT
J Child Neurol; 2008 Oct; 23(10):1136-48. PubMed ID: 18952580
[TBL] [Abstract][Full Text] [Related]
42. Long-term survival and complete response of a patient with recurrent diffuse intrinsic brain stem glioblastoma multiforme.
Burzynski SR; Lewy RI; Weaver R; Janicki T; Jurida G; Khan M; Larisma CB; Paszkowiak J; Szymkowski B
Integr Cancer Ther; 2004 Sep; 3(3):257-61. PubMed ID: 15312271
[TBL] [Abstract][Full Text] [Related]
43. Use of ERC-1671 Vaccine in a Patient with Recurrent Glioblastoma Multiforme after Progression during Bevacizumab Therapy: First Published Report.
Bota DA; Alexandru-Abrams D; Pretto C; Hofman FM; Chen TC; Fu B; Carrillo JA; Schijns VE; Stathopoulos A
Perm J; 2015; 19(2):41-6. PubMed ID: 25785641
[TBL] [Abstract][Full Text] [Related]
44. The role of brachytherapy in the treatment of glioblastoma multiforme.
Barbarite E; Sick JT; Berchmans E; Bregy A; Shah AH; Elsayyad N; Komotar RJ
Neurosurg Rev; 2017 Apr; 40(2):195-211. PubMed ID: 27180560
[TBL] [Abstract][Full Text] [Related]
45. Standard therapy for glioblastoma--a review of where we are.
Nishikawa R
Neurol Med Chir (Tokyo); 2010; 50(9):713-9. PubMed ID: 20885105
[TBL] [Abstract][Full Text] [Related]
46. Anticancer drug-loaded hydrogels as drug delivery systems for the local treatment of glioblastoma.
Bastiancich C; Danhier P; Préat V; Danhier F
J Control Release; 2016 Dec; 243():29-42. PubMed ID: 27693428
[TBL] [Abstract][Full Text] [Related]
47. Current status of intratumoral therapy for glioblastoma.
Mehta AI; Linninger A; Lesniak MS; Engelhard HH
J Neurooncol; 2015 Oct; 125(1):1-7. PubMed ID: 26233248
[TBL] [Abstract][Full Text] [Related]
48. Management of glioblastoma after recurrence: A changing paradigm.
Mallick S; Benson R; Hakim A; Rath GK
J Egypt Natl Canc Inst; 2016 Dec; 28(4):199-210. PubMed ID: 27476474
[TBL] [Abstract][Full Text] [Related]
49. Surgery for Glioblastoma in Elderly Patients.
Conti Nibali M; Gay LG; Sciortino T; Rossi M; Caroli M; Bello L; Riva M
Neurosurg Clin N Am; 2021 Jan; 32(1):137-148. PubMed ID: 33223022
[TBL] [Abstract][Full Text] [Related]
50. Combined-therapeutic strategies synergistically potentiate glioblastoma multiforme treatment
Yang J; Shi Z; Liu R; Wu Y; Zhang X
Theranostics; 2020; 10(7):3223-3239. PubMed ID: 32194864
[TBL] [Abstract][Full Text] [Related]
51. Personalized medicine in neurosurgery.
Nicolaidis S
Metabolism; 2013 Jan; 62 Suppl 1():S45-8. PubMed ID: 23018147
[TBL] [Abstract][Full Text] [Related]
52. Treatment of glioblastoma multiforme: a new standard.
Henson JW
Arch Neurol; 2006 Mar; 63(3):337-41. PubMed ID: 16533960
[No Abstract] [Full Text] [Related]
53. [Methods of regional and local chemotherapy in the treatment of malignant tumors of the brain].
Romodanov AP; Sosnov IuD
Vestn Akad Med Nauk SSSR; 1974; (11):83-6. PubMed ID: 4375359
[No Abstract] [Full Text] [Related]
54. Current Perspectives on Therapies, Including Drug Delivery Systems, for Managing Glioblastoma Multiforme.
Bhaskaran M; Devegowda VG; Gupta VK; Shivachar A; Bhosale RR; Arunachalam M; Vaishnavi T
ACS Chem Neurosci; 2020 Oct; 11(19):2962-2977. PubMed ID: 32945654
[TBL] [Abstract][Full Text] [Related]
55. Glioblastoma: therapeutic challenges, what lies ahead.
Lima FR; Kahn SA; Soletti RC; Biasoli D; Alves T; da Fonseca AC; Garcia C; Romão L; Brito J; Holanda-Afonso R; Faria J; Borges H; Moura-Neto V
Biochim Biophys Acta; 2012 Dec; 1826(2):338-49. PubMed ID: 22677165
[TBL] [Abstract][Full Text] [Related]
56. Standard therapy or additionally radioactive iodine (131I) therapy; which will stop the recurrence of glioblastoma multiforme (GBM)?
Czarnywojtek A; Gut P; Dyrka K; Sowiński J; Sawicka-Gutaj N; Katulska K; Stajgis P; Wykrętowicz M; Moskal J; Kościński J; Pietrończyk K; Graczyk P; Krawczyński MR; Florek E; Szczepanek-Parulska E; Ruchała M; Ferlito A
Endokrynol Pol; 2024; 75(2):130-139. PubMed ID: 38646982
[TBL] [Abstract][Full Text] [Related]
57. Rethinking Glioblastoma Therapy: MDA-9/Syntenin Targeted Small Molecule.
Das SK; Sarkar D; Cavenee WK; Emdad L; Fisher PB
ACS Chem Neurosci; 2019 Mar; 10(3):1121-1123. PubMed ID: 30681320
[TBL] [Abstract][Full Text] [Related]
58. A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme.
Guzmán M; Duarte MJ; Blázquez C; Ravina J; Rosa MC; Galve-Roperh I; Sánchez C; Velasco G; González-Feria L
Br J Cancer; 2006 Jul; 95(2):197-203. PubMed ID: 16804518
[TBL] [Abstract][Full Text] [Related]
59. Biocompatible copolymer formulations to treat glioblastoma multiforme.
Erthal LCS; Gobbo OL; Ruiz-Hernandez E
Acta Biomater; 2021 Feb; 121():89-102. PubMed ID: 33227487
[TBL] [Abstract][Full Text] [Related]
60. Natural Bioactive Compounds: Alternative Approach to the Treatment of Glioblastoma Multiforme.
Desai V; Bhushan A
Biomed Res Int; 2017; 2017():9363040. PubMed ID: 29359162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
